MyBlueDotsAlentis Announces Positive Topline Results from Two Studies of Lixudebart (ALE.F02) in Patients with ANCA-RPGN and Advanced Liver Fibrosis MyBlueDots5 months ago01 mins BASEL, Switzerland–(BUSINESS WIRE)–Demonstrated Robust Dose-Dependent Target Engagement, Preliminary Evidence of Improved Organ Function and a Favorable Safety Profile Post navigation Previous: Henry Schein Opens Customer Emergency Support Hotline in Response to California FiresNext: What Illinois residents should know, following the first US death from bird virus
‘Master control switch’ protein that heightens neurodegenerative disease offers new treatment target MyBlueDots4 days ago 0
New findings reveal how the heart is organized from the earliest stages of embryonic development MyBlueDots4 days ago 0
Scholastic performance is a key concern for young cancer patients, study finds MyBlueDots4 days ago 0